Your session is about to expire
← Back to Search
Quadruple Drug Therapy for Multiple Myeloma
Study Summary
This trial is testing a new combination of drugs to treat multiple myeloma. The drugs work in different ways to stop the growth of cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive.I have a stomach or intestine condition that affects how I absorb pills or have trouble swallowing.You have enough infection-fighting white blood cells in your body.Your hemoglobin level is at least 8.0 grams per deciliter.Your total bilirubin levels are not more than 1.5 times the upper limit of normal.I haven't had any cancer other than non-melanoma skin cancer or in situ carcinoma, or if I have, it was more than 2 years ago and fully treated.I am not on any other experimental treatments but can take bisphosphonates.My heart condition is stable and any ECG irregularities are not a concern.You have hepatitis B or active hepatitis C infection.I am able to care for myself and perform daily activities.I have myeloma and have had minimal or no treatment, but some specific treatments are okay.You are okay with giving bone marrow and blood samples for research.I haven't taken any strong medication that affects liver enzymes in the last 2 weeks.My kidneys are functioning well enough, with a creatinine clearance of at least 30 mL/min.I experience significant numbness, tingling, or pain in my hands or feet.Women who could become pregnant must have a negative pregnancy test within 7 days before joining the study.I had radiotherapy less than 2 weeks ago, or 1 week ago for a small area.You are allergic to corticosteroids, monoclonal antibodies, human proteins, or any ingredients in these medications.I am of childbearing age and do not plan to use birth control.I have been diagnosed with MGUS or smoldering myeloma.Your platelet count without receiving a blood transfusion is 75,000 or higher per cubic millimeter.Your liver enzymes (ALT and AST) are not more than 2.5 times the normal upper limit.I don't have any serious health or mental conditions that could stop me from completing the treatment.I am currently breastfeeding.I have not had major surgery in the last 14 days.I have mild or no diarrhea without taking medicine for it.My multiple myeloma can be measured by medical tests.
- Group 1: Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Daratumumab carry a high risk for adverse side effects?
"Since this is a phase 2 trial, there is only preliminary data supporting the safety of Daratumumab. No efficacy data exists yet."
What are some of the primary medical conditions that Daratumumab has been approved to treat?
"Daratumumab is most often used to treat ophthalmia and sympathetic. However, it can also be helpful for patients suffering from at least two prior systemic chemotherapy regimens, branch retinal vein occlusion, and macular edema."
Are we currently able to enroll patients in this research project?
"This study is not accepting patients at the moment. The first posting was on April 12th, 2017 and there was a September 8th, 2022 update. However, if you're looking for other trials, 839 are enrolling patients with multiple myeloma while 794 studies are recruiting participants who Daratumumab might help."
What is the projected or expected enrollment for this clinical trial?
"Presently, this clinical trial is not recruiting new patients. The study was originally advertised on April 12th, 2017 and underwent its most recent edit on September 8th, 2022. If you are seeking other trials, there are 839 active studies for multiple myeloma and 794 for Daratumumab that presently have open enrollment."
Share this study with friends
Copy Link
Messenger